- Home
- SPRO vs TTP Comparison
SPRO vs TTP Comparison
Compare SPRO & TTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- TTP
- Stock Information
- Founded
- SPRO 2013
- TTP 2011
- Country
- SPRO United States
- TTP United States
- Employees
- SPRO N/A
- TTP N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- TTP Trusts Except Educational Religious and Charitable
- Sector
- SPRO Health Care
- TTP Finance
- Exchange
- SPRO Nasdaq
- TTP Nasdaq
- Market Cap
- SPRO 74.0M
- TTP 68.3M
- IPO Year
- SPRO 2017
- TTP N/A
- Fundamental
- Price
- SPRO $1.31
- TTP $41.25
- Analyst Decision
- SPRO Strong Buy
- TTP
- Analyst Count
- SPRO 3
- TTP 0
- Target Price
- SPRO $7.00
- TTP N/A
- AVG Volume (30 Days)
- SPRO 124.6K
- TTP 8.4K
- Earning Date
- SPRO 08-05-2024
- TTP 01-01-0001
- Dividend Yield
- SPRO N/A
- TTP 7.61%
- EPS Growth
- SPRO N/A
- TTP N/A
- EPS
- SPRO 0.33
- TTP N/A
- Revenue
- SPRO $118,459,000.00
- TTP N/A
- Revenue This Year
- SPRO N/A
- TTP N/A
- Revenue Next Year
- SPRO N/A
- TTP N/A
- P/E Ratio
- SPRO $4.12
- TTP N/A
- Revenue Growth
- SPRO 118.43
- TTP N/A
- 52 Week Low
- SPRO $0.99
- TTP $24.75
- 52 Week High
- SPRO $1.89
- TTP $31.22
- Technical
- Relative Strength Index (RSI)
- SPRO 51.95
- TTP 61.30
- Support Level
- SPRO $1.32
- TTP $41.63
- Resistance Level
- SPRO $1.37
- TTP $42.06
- Average True Range (ATR)
- SPRO 0.05
- TTP 0.49
- MACD
- SPRO 0.00
- TTP -0.23
- Stochastic Oscillator
- SPRO 41.18
- TTP 46.49
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About TTP Tortoise Pipeline & Energy Fund Inc.
Tortoise Pipeline & Energy Fund Inc is a non-diversified, closed-end investment management company. It invests in equity securities of North American pipeline companies that transport natural gas, natural gas liquids, crude oil, and refined products. The company seeks to invest in fixed-income and dividend-paying equity securities of power and energy infrastructure companies that provide stable and defensive characteristics throughout economic cycles.